{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Severity of treatment-emergent adverse events as assessed by the NCI CTCAE Version 5.0. This outcome measure applies only to participants in the dose escalation cohorts.","groups":[{"description":"SBT6050 plus trastuzumab deruxtecan\n\nSBT6050: Dosed with 0.45 mg/kg by subcutaneous (SC) injection in 21-day cycles\n\ntrastuzumab deruxtecan: 6.4 mg/kg by IV infusion in 21-day cycles","id":"OG000","title":"SBT6050 + T-DXd (6.4 mg/kg)"},{"description":"SBT6050 plus tucatinib and trastuzumab\n\nSBT6050: Dosed with 0.45 mg/kg by subcutaneous (SC) injection in 21-day cycles\n\ntucatinib: 300 mg by mouth (PO) twice daily (BID)\n\ntrastuzumab: 8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles","id":"OG001","title":"SBT6050 + Tucatinib + Trastuzumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who were enrolled and treated with at least 1 dose of SBT6050.","reportingStatus":"POSTED","timeFrame":"18 weeks","title":"Number of Participants With Treatment-emergent Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}